Bruker's ClinProt Mass Spec Platform to Help
HealthLinx Develop IVD Biomarker Assays

HealthLinx of Melbourne, Australia, will use Bruker Daltonics' mass spectrometry-based protein biomarker platform to develop diagnostic assays, the company said this week.

In collaboration with Bruker, HealthLinx plans to develop in vitro diagnostic tests for both research and clinical diagnostics using Bruker's MALDI-TOF mass spectrometer and its ClinProt magnetic bead sample preparation technology and software.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

A new analysis examines the gender gap among paper authors in the sciences and says it may take decades or more to close.

Researchers have uncovered signals of selection that may enable the Bajau people to free five hundreds of feet deep, Reuters reports.

In Science this week: paternally inherited cis-regulatory structural variants in autism, and more.

A new report outlines issues facing the implementation of personalized medicine in the UK, the Independent reports.